Quantcast

Latest Chemical pathology Stories

2014-01-29 16:28:58

CINCINNATI, Jan. 29, 2014 /PRNewswire-USNewswire/ -- Researchers have developed a tool that allows caregivers to quickly and accurately predict the risk of death in children with septic shock - a systemic infection that damages vital organs and one of the leading causes of death among hospitalized children. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) Reporting their results Jan. 29 in PLOS ONE (published by the Public Library of Science), researchers say the...

2014-01-28 12:29:07

New UPLC System and Columns Drive Separations Efficiency and the Sensitivity of LC-MS Analyses to New Levels MILFORD, Mass., Jan. 28, 2014 /PRNewswire/ -- Waters Corporation (WAT:NYSE) today introduced the new Waters(®) ACQUITY( )UPLC(®) M-Class System, an industry-first nano- to microscale UltraPerformance LC(®) (UPLC(®)) system rated for 15,000 psi operation. Coupled to Waters mass spectrometers, the system delivers the sensitivity to quantify and to identify vanishingly...

2014-01-22 23:20:45

A new study published online today in The Oncologist journal shows that an assessment of metabolic response in patients with metastatic colon cancer (mCC) treated with a single course of chemotherapy could predict the downstream efficacy of the treatment. The Engelmann study showed that PET, applied after a single cycle of first-line systemic therapy predicted progression-free survival. Durham, NC (PRWEB) January 22, 2014 A new study published online today in The Oncologist journal shows...

2014-01-13 23:21:16

This report from BCC Research is an exhaustive study on the cancer profiling and pathways, giving crucial statistics and analysis on the market structure, market size, key technologies, and segments, important trends in technology development, next-generation technologies, major opportunities and market shares of key players and innovative drugs. Wellesley, Mass (PRWEB) January 13, 2014 According to a new technical market research report, Cancer Profiling and Pathways: Technologies and...

2014-01-13 08:28:33

The company's SnapPath® system facilitates personalized medicine MOUNTAIN VIEW, Calif., Jan. 13, 2014 /PRNewswire/ -- Based on its recent analysis of the cancer diagnostics market, Frost & Sullivan recognizes BioMarker Strategies LLC with the 2013 North American Frost & Sullivan Award for Technology Innovation Leadership. BioMarker Strategies has pioneered the development and validation of SnapPath®, a novel platform for live tumor cell processing and testing. This rapid, robust and...

2014-01-13 04:21:04

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ -- Study supported by a EUR3.5 million IWT grant from the Flemish Government arGEN-X, a clinical stage human therapeutic antibody company, announces that it has advanced ARGX-110, a novel anti-CD70 antibody, into the safety and efficacy expansion part of its Phase Ib study. The objective is to further investigate the safety of ARGX-110 in CD70-positive cancer patients with either...

2014-01-13 00:22:35

The NBDA Intends to Change the Dismal Success Rate of Biomarkers by Creating Evidence Based, End-to-End Biomarker Development Processes A Collaborative Network-Based, Non-Profit Organization, the NBDA Will Create Standards to Successfully Develop Biomarkers Needed for Precision (personalized) Medicine WASHINGTON, Jan. 13, 2014 /PRNewswire-USNewswire/ -- The launch of a new independent, non-profit organization, the National Biomarker Development Alliance (NBDA), broadly engaging...

2014-01-07 08:30:19

SCCM Event Examines Groundbreaking AKI Risk Assessment Biomarkers SAN DIEGO, Jan. 7, 2014 /PRNewswire/ -- An international panel of critical care experts will discuss how new biomarkers for risk assessment of acute kidney injury (AKI) could affect care of critically ill patients at a symposium being held in conjunction with the Society of Critical Care Medicine (SCCM) 43rd Critical Care Congress in San Francisco, Calif. Astute Medical, Inc. is sponsoring the event "Early AKI Assessment: Are...

2013-12-31 08:22:46

Following the Successful Utilization of A3 Adenosine Receptor Biomarker in Can-Fite's Phase IIb Rheumatoid Arthritis Study PETACH TIKVA, Israel, Dec. 31, 2013 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the following: The Company's subsidiary, OphthaliX Inc. (OTCQB: OPLI), will conduct a retrospective analysis...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related